Fundraising FoxDecheng Capital — 2021 Investments
4 investments dated 2021 · listed companies and verified rows first · show all
Imviva is a clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for oncology and autoimmune diseases.
BiotechDeep TechHealthtechMedical Devices
Jiangtao Ren(Chief Scientific Officer)Lu Han(Chief Executive Officer)Yajin Ni(Chief Technology Officer)Jan Davidson(Chief Medical Officer)
Co-investorsGL VenturesHillhouse CapitalShenzhen Capital Group
Cellares develops automated manufacturing systems and technology platforms to accelerate the production and commercialization of cell therapies.
Advanced ManufacturingBiotechMedical DevicesSouth San Francisco, US
Fabian Gerlinghaus(Co-Founder & CEO)inOmar Kurdi(Co-Founder & President)inAlex Pesch(Founder)Fabian Gerlinghaus Omar Kurdi(Founder)
BoardJustin Butler(Director)inVictor Tong(Director)in
Co-investors8VCEcoR1 CapitalIntuitive VenturesKoch Disruptive TechnologiesBaillie GiffordBlackRock+4 more
BiotechSeattle, US
Mitchell Gold(Executive Chairman and Chief Executive Officer)inMichael Kornacker(Executive Officer, Director)inRyan Swanson(Executive Officer, Director)inDavid Miller(Executive Officer, Director)inJames Paul Rickey(Senior Vice President and Chief Financial Officer)Mark James Litton(President and Chief Operating Officer)
Co-investorsFrazier Life SciencesBiotechnology Value FundOrbiMed
Covid test maker that went public at a $2.3 billion valuation.
Clint Sever(Founder)in
Co-investorsACME CapitalDarwin CapitalDentsu VenturesForesite CapitalMothership VCPrime Partners+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.